Navigation Links
Cadence Pharmaceuticals' CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2008
Date:4/30/2008

SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder will present the company's corporate overview at the following investment conferences:

-- Deutsche Bank's 33rd Annual Healthcare Conference at the

InterContinental Hotel in Boston on Tuesday, May 6, 2008 at 2:10pm

Eastern Time (11:10am Pacific Time)

-- Bank of America's 2008 Healthcare Conference at the Four Seasons Hotel

in Las Vegas on Wednesday, May 14, 2008 at 4:00pm Pacific Time (7:00pm

Eastern Time)

-- JMP Securities' Seventh Annual Research Conference at the Ritz-Carlton

Hotel in San Francisco on Wednesday, May 21, 2008 at 12:00pm Pacific

Time (3:00pm Eastern Time)

Each presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at http://www.cadencepharm.com. To access the presentations, click on the Investor Relations tab the link entitled "Events and Presentations" on the left side of the screen. A replay of each webcast will available approximately one hour after the live webcast concludes and will remain available for 30 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.

Cadence(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.

Contacts: William R. LaRue Anna Gralinska

SVP & Chief Financial Officer Director, Investor Relations

Cadence Pharmaceuticals, Inc. Cadence Pharmaceuticals, Inc.

858-436-1400 (858) 436-1452


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston
2. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
3. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
4. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIO Investor Forum
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference
10. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 29, 2017 WuXi Biologics, a leading ... to biologics and a WuXi AppTec Affiliate, today ... Best Bioprocessing Excellence Award from IMAPAC, a leading ... aims to recognize outstanding leaders and trend-setters of ... bioprocessing and biomanufacturing experts in the industry, along ...
(Date:3/29/2017)... Tx (PRWEB) , ... March 29, 2017 , ... ... honored to announce that Nerium International Mexico has been approved as an active ... works to achieve satisfaction and protection among distributers and consumers in relationship marketing. ...
(Date:3/29/2017)... Mass. , March 29, 2017 /PRNewswire/ ... in applying mechanistic modeling to drug research ... their collaboration with Zymeworks Inc. for quantitative ... conjugate therapeutics intended for the treatment of ... supported Zymeworks previously for GLP toxicology studies ...
(Date:3/29/2017)... ... March 29, 2017 , ... On the heels of ... research, Colpitts Clinical Trial Travel has announced that it will manage travel services for ... among the first in the United States and Europe to offer travel management services ...
Breaking Biology Technology:
(Date:2/28/2017)... News solutions for biometrics, bag drop and New ADA-compliant kiosk ... At PTE 2017 ... Materna will present its complete end-to-end passenger journey, from ... benefit for passengers. To accelerate the whole passenger handling process, ... to take passengers through the complete integrated process with a ...
(Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader of ... elite iris biometric solution on the latest Qualcomm® ... at Mobile World Congress 2017 (February 27 ... in Hall 3, Stand 3E10. ... Haven™ security platform—a combination of hardware, software ...
(Date:2/16/2017)... Feb. 16, 2017  Genos, a community for ... it has received Laboratory Accreditation from the College ... presented to laboratories that meet stringent requirements around ... rigorous processes. "Genos is committed to ... practices. We,re honored to be receiving CAP accreditation," ...
Breaking Biology News(10 mins):